Related Experiment Video
Updated: May 4, 2026

Autologous Blood Injection to Model Spontaneous Intracerebral Hemorrhage in Mice
Published on: August 24, 2011
Reversal of trauma-induced amnesia in mice by a thrombin receptor antagonist
Zeev Itzekson1, Nicola Maggio, Anat Milman
1Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University, 6997801, Tel Aviv, Israel.
Abstract:
Minimal traumatic brain injury (mTBI) is associated with the existence of retrograde amnesia and microscopic bleeds containing activated coagulation factors. In an mTBI model, we report that thrombin induces amnesia through its receptor protease-activated receptor 1 (PAR-1). Thrombin activity was significantly elevated (32 %, p < 0.05) 5 min following mTBI compared to controls. Amnesia was assessed by the novel object recognition test in mTBI animals and in animals injected intracerebroventricularly (ICV) with either thrombin or a PAR-1 agonist 1 h after the acquisition phase. Saline-injected controls had a preference index of over 0.3 while mTBI animals and those injected with thrombin or the PAR-1 agonist spent equal time with both objects indicating no recall of the object presented to them 24 h previously (p < 0.05). Co-injecting a PAR-1 antagonist (SCH79797) completely blocked the amnestic effects of mTBI, thrombin, and the PAR-1 agonist. Long-term potentiation, measured in hippocampal slices 24 h after mTBI, ICV thrombin or the PAR-1 agonist, was significantly impaired and this effect was completely reversed by the PAR-1 antagonist. The results support a crucial role for PAR-1 in the generation of amnesia following mTBI, revealing a novel therapeutic target for the cognitive effects of brain trauma.
Insights
Minimal traumatic brain injury (mTBI) causes amnesia by activating thrombin, which acts via protease-activated receptor 1 (PAR-1). Blocking PAR-1 prevents these memory deficits, offering a new therapeutic target for brain trauma.
Area of Science:
- Neuroscience
- Traumatic Brain Injury Research
- Coagulation Factor Research
Background:
- Minimal traumatic brain injury (mTBI) is linked to memory loss and bleeding.
- Activated coagulation factors, particularly thrombin, are implicated in mTBI-related amnesia.
Purpose of the Study:
- To investigate the role of thrombin and its receptor PAR-1 in mTBI-induced amnesia.
- To explore PAR-1 as a potential therapeutic target for cognitive deficits following brain trauma.
Main Methods:
- Assessed amnesia using the novel object recognition test in an mTBI model.
- Measured thrombin activity and long-term potentiation (LTP) in hippocampal slices.
- Utilized PAR-1 agonists and antagonists (SCH79797) in intracerebroventricular injections.
Main Results:
- Thrombin activity increased significantly post-mTBI.
- mTBI, thrombin, and PAR-1 agonist induced amnesia, impairing object recognition.
- PAR-1 antagonist SCH79797 completely blocked amnesia and restored LTP.
- LTP was impaired by mTBI and thrombin, but reversed by the antagonist.
Conclusions:
- Thrombin signaling through PAR-1 plays a critical role in mTBI-induced amnesia.
- Targeting PAR-1 presents a novel therapeutic strategy for cognitive impairments after brain injury.

